3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
92
Polycystic Ovary Syndrome
10
Neoplasm Metastasis
7
Carcinoma, Ductal, Breast
5
Infertility
4
Carcinoma, Lobular
4
Osteoporosis
3
Neoplasms, Hormone-Dependent
3
Neoplasms
3
Breast Neoplasms, Male
3
Advanced Breast Cancer
3
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Breast Carcinoma In Situ
2
Bone Diseases, Metabolic
2
Unilateral Breast Neoplasms
1
Recurrence
1
Peritoneal Neoplasms
1
Ovarian Neoplasms
1
Osteitis Deformans
1
Obesity
1
Neoplasms by Site
1
Multiple Endocrine Neoplasia Type 1
1
Low Grade Serous Ovarian Cancer
1
Infertility, Female
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Hereditary Breast and Ovarian Cancer Syndrome
1
HR+/HER2- Breast Cancer
1
HER2+ Breast Cancer
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
Letrozole
×
Clear all
NCT06760637
2026-05-19
FourLight-3
Pfizer
Phase 3
Active not recruiting
1,035 enrolled